Back to Search
Start Over
Combined tumorāassociated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma
- Source :
- Hematological Oncology. 39:625-638
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Primary central nervous system lymphoma (PCNSL) is an aggressive and rare malignancy with poor prognosis. However, there are no reliable prognostic biomarkers for PCNSL in clinical practice. Here, we aimed to identify a reliable prognostic biomarker for predicting the survival of PCNSL patients. In this study, multiplex immunofluorescence and digital imaging analysis were used to characterize tumor-associated macrophages (TAMs) immunophenotypes and the expression of programmed cell death ligand 1 on TAMs, with regard to prognosis from diagnostic tumor tissue samples of 59 PCNSL patients. We found that the M2-to-M1 ratio was a more reliable prognostic biomarker for PCNSL than M1-like or M2-like macrophage infiltration. In addition, the combination of programmed death-ligand 1 (PD-L1) expression on TAMs and the M2-to-M1 ratio in PCNSL demonstrated improved performance in prognostic discrimination than PD-L1-positive TAMs or M2-to-M1 ratio. To validate the prognostic significance of the combined TAMs associated biomarkers, they were integrated into the International Extranodal Lymphoma Study Group (IELSG) index and termed as IELSG-M index. Kaplan-Meier plots showed that the IELSG-M index could discriminate patients into low-, intermediate- or high-risk subgroups, better than IELSG, in terms of prognosis. The areas under the receiver operating characteristic curves of IELSG-M was 0.844 for overall survival; superior to the IELSG model (0.580). Taken together, this study's findings showed that the combination of PD-L1 on TAMs and the M2-to-M1 ratio could be strong prognostic predictive biomarkers for PCNSL and the IELSG-M index had improved prognostic significance than the IELSG index.
- Subjects :
- Male
Oncology
Cancer Research
medicine.medical_specialty
Poor prognosis
Lymphoma
Malignancy
B7-H1 Antigen
Programmed cell death ligand 1
Central Nervous System Neoplasms
hemic and lymphatic diseases
Internal medicine
PD-L1
Tumor-Associated Macrophages
Biomarkers, Tumor
Tumor Microenvironment
medicine
Humans
Retrospective Studies
Receiver operating characteristic
biology
business.industry
Primary central nervous system lymphoma
Hematology
General Medicine
Middle Aged
Prognosis
medicine.disease
Survival Rate
Improved performance
biology.protein
Biomarker (medicine)
Female
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 10991069 and 02780232
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- Hematological Oncology
- Accession number :
- edsair.doi.dedup.....dd03657b8d408dd4582d20e2a506c4ea